Clinical trials: in Saudi Arabia
Beta-thalassemia Major, Hemosiderosis
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available.
- Conditions
- Beta-thalassemia Major, Hemosiderosis, Iron Overload, Rare Anemia
- Trial name
- ESCALATOR (NCT00171301)
- Testing
- Deferasirox
- Where
- 5 sites in Egypt, Lebanon and 3 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Diagnostic Imaging
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study.
- Trial name
- IMAGE (NCT00876083)
- Testing
- Ultravist (Iopromide, BAY86-4877)
- Where
- 21 sites in Bosnia and Herzegovina, China and 19 more
- Volunteers
- 44,920 people
- Sponsor
- Bayer
Male, Hypogonadism
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
This is an observational study with a drug called Nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism.
- Trial name
- IPASS Nebido (NCT00410306)
- Testing
- Testosterone Undecanoate (Nebido, BAY86-5037)
- Where
- 33 sites in Australia, Austria and 31 more
- Volunteers
- 1,493 people
- Sponsor
- Bayer
Smoking Cessation
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation.
- Trial name
- NCT00594204
- Testing
- varenicline tartrate (CP-526, 555-18)
- Where
- 42 sites in Brazil, Colombia and 9 more
- Volunteers
- 593 people
- Sponsor
- Pfizer
Hypertension
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen.
- Trial name
- ACTUAL (NCT00708344)
- Testing
- Irbesartan - Hydrochlorothiazide
- Where
- 16 sites in Algeria, Argentina and 14 more
- Volunteers
- 832 people
- Sponsor
- Sanofi
Major Depressive Disorder
Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months
In usual clinical conditions, depressed patients with no sexual dysfunction, after signing their consent for the dissemination of their clinical information will begin their treatment with any SSRI or a Dual antidepressant as per…
- Trial name
- NCT00561509
- Testing
- SSRIs, Dual antidepressants
- Where
- 57 sites in Austria, China and 11 more
- Volunteers
- 1,626 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes
This is an open label, two arms, randomized, unblinded phase 2 study in patients with locally advanced or metastatic breast cancer who have been previously treated with anthracycline with/without taxane based regimen in the…
- Trial name
- NCT00192101
- Testing
- gemcitabine, cisplatin
- Where
- Saudi Arabia
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Mesothelioma
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
- Trial name
- NCT00040625
- Testing
- Pemetrexed, Cisplatin
- Where
- 6 sites in United States, Brazil and 2 more
- Sponsor
- Eli Lilly and Company
Sepsis
The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis
Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction.
- Trial name
- NCT00045760
- Testing
- Drotrecogin alfa (activated)
- Where
- 426 sites in United States, Australia and 30 more
- Sponsor
- Eli Lilly and Company